Chk1 knockdown confers radiosensitization in prostate cancer stem cells

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2247-2254

  Wang, Xiaobin ^a   Ma, Zhikun ^a   Xiao, Zheng ^a   Liu, Hui ^a   Dou, Zhongling ^a   Feng, Xiaoshan ^a   Shi, Haijun ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Cancer stem cells; Chk1; Prostate cancer

Indexed keywords

CASPASE 2; CD133 ANTIGEN; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 1; HERMES ANTIGEN; PROTEIN TYROSINE PHOSPHATASE; SHORT HAIRPIN RNA;

APOPTOSIS; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHK1 GENE; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MITOSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION;

ANTIGENS, CD; ANTIGENS, CD44; APOPTOSIS; CASPASE 2; CDC25 PHOSPHATASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN B; DNA REPAIR; GLYCOPROTEINS; HUMANS; MALE; MITOSIS; NEOPLASTIC STEM CELLS; PEPTIDES; PROSTATIC NEOPLASMS; PROTEIN KINASES; RADIATION TOLERANCE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84868116065     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2068     Document Type: Conference Paper

References (40)

1. Neppl-Huber C, Zappa M, Coebergh JW, et al: Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol 23:1325-1334, 2012.
2. Heidenreich A, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61-71, 2011.
3. Bonkhoff H: Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer 2012:593241, 2012.
4. Beckendorf V, Guerif S, Le PE, et al: 70 Gy versus 80 Gy in localized prostate cancer:5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80:1056-1063, 2011.
5. Merry C, Fu K, Wang J, Yeh IJ and Zhang Y: Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 9:279-283, 2010.
6. Stracker TH, Usui T and Petrini JH: Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair 8:1047-1054, 2009.
7. Jackson SP and Bartek J: The DNA-damage response in human biology and disease. Nature 461:1071-1078, 2009.
8. Diehn M and Clarke MF: Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98:1755-1757, 2006. (Pubitemid 46017927)
9. Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8:545-554, 2008. (Pubitemid 351881850)
10. Hittelman WN, Liao Y, Wang L and Milas L: Are cancer stem cells radioresistant. Future Oncol 6:1563-1576, 2010.
11. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768, 2008.
12. Eyler CE and Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26:2839-2845, 2008.
13. Wang G, Wang Z, Sarkar FH and Wei W: Targeting prostate cancer stem cells for cancer therapy. Discov Med 13:135-142, 2012.
14. Maitland NJ and Collins AT: Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26:2862-2870, 2008.
15. Wu J, Lai G, Wan F, et al: Knockdown of checkpoint kinase 1 is associated with the increased radiosensitivity of glioblastoma stem-like cells. Tohoku J Exp Med 226:267-274, 2012.
16. Xiao Z, Liu Q, Zhao B, Wu J and Lei T: Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1α signaling pathway. Oncol Rep 26:1457-1464, 2011.
17. Ma CX, Janetka JW and Piwnica-Worms H: Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17:88-96, 2011.
18. Carrassa L and Damia G: Unleashing Chk1 in cancer therapy. Cell Cycle 10:2121-2128, 2011.
19. Chen Y and Sanchez Y: Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair 3:1025-1032, 2004. (Pubitemid 38997944)
20. Lang SH, Frame FM and Collins AT: Prostate cancer stem cells. J Pathol 217:299-306, 2009.
21. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951, 2005. (Pubitemid 41713363)
22. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037, 2007.
23. Tang DG, Patrawala L, Calhoun T, et al: Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 46:1-14, 2007. (Pubitemid 46095228)
24. Wei C, Guomin W, Yujun L and Ruizhe Q: Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line. Cancer Biol Ther 6:763-768, 2007. (Pubitemid 47328359)
25. Syljuasen RG, Sorensen CS, Hansen LT, et al: Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 25:3553-3562, 2005. (Pubitemid 40559562)
26. Binder A and Bohm L: Influence of irradiation and pentoxifylline on histone H3 phosphorylation in human tumour cell lines. Cell Prolif 35:37-47, 2002. (Pubitemid 34592060)
27. Sorensen CS, Hansen LT, Dziegielewski J, et al: The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7:195-201, 2005. (Pubitemid 40268135)
28. Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE and Stambrook PJ: The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27:3977-3985, 2008. (Pubitemid 351913634)
29. Xiao Z, Chen Z, Gunasekera AH, et al: Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 278:21767-21773, 2003. (Pubitemid 36792580)
30. Sanchez Y, Wong C, Thoma RS, et al: Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497-1501, 1997. (Pubitemid 27449236)
31. Sorensen CS, Melixetian M, Klein DK and Helin K: NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling. Cell Cycle 9:450-455, 2010.
32. Sidi S, Sanda T, Kennedy RD, et al: Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133:864-877, 2008. (Pubitemid 351715394)
33. Dumont F, Altmeyer A and Bischoff P: Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opin Ther Pat 19:775-799, 2009.
34. Yang H, Yoon SJ, Jin J, et al: Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun 406:53-58, 2011.
35. Meuth M: Chk1 suppressed cell death. Cell Div 5:21, 2010.
36. Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108:73-112, 2010.
37. Gao Q, Zhou J, Huang X, et al: Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol Ther 13:928-937, 2006.
38. Freytag SO, Stricker H, Pegg J, et al: Phase I study of replicationcompetent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res 63:7497-7506, 2003. (Pubitemid 37413494)
39. Geoerger B, Van Beusechem VW, Opolon P, et al: Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 7:584-594, 2005. (Pubitemid 40744524)
40. Tsuruta Y, Pereboeva L, Breidenbach M, et al: A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 14:3582-3588, 2008.